ChromaDex Corporation (OCD1.F)

3,2400 -0,2800 (-7,95%) Alla chiusura: 09:24AM CEST

ChromaDex Corporation

10900 Wilshire Blvd
Suite 600
Los Angeles, CA 90024
United States
310 388 6706
https://www.chromadex.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 106

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Frank Louis Jaksch Jr.	Co-Founder & Chairman	65,12k	N/D	1968
Mr. Robert N. Fried	CEO & Director	715,31k	N/D	1960
Ms. Brianna Gerber	Chief Financial Officer	448,52k	N/D	1981
Dr. Andrew Shao Ph.D.	Senior Vice President of Global Regulatory & Scientific Affairs	N/D	N/D	N/D
Heather Van Blarcom	Senior VP of Legal & Corporate Secretary	N/D	N/D	N/D
Alex Worsham	Vice President of Global Marketing & Communications	N/D	N/D	N/D
Mr. David Kroes	Senior Vice President of People Matters	N/D	N/D	N/D
Ms. Chu Yan	Managing Director of Asia Pacific	N/D	N/D	N/D
Mr. Jason Campbell	Senior Vice President of Business Development	N/D	N/D	N/D
Kendall Knysch	Head of Media Relations & Partnerships	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Governance aziendale

L'ISS Governance QualityScore di ChromaDex Corporation al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 6; diritti degli azionisti: 2; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.